ARCT - Arcturus Therapeutics Holdings Stock

Market Summary

USD26.92+0.41

Market Closed

1.55%

ARCT Alerts

1 major insider sales recently.
Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

Market Cap

715.4M

Price/Earnings (Trailing)

8.91

Price/Sales (Trailing)

2.7

EV/EBITDA

156.39

Price/Free Cashflow

5.69

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

72.38%

Return on Equity

33.8%

Return on Assets

23.63%

Free Cashflow Yield

17.58%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

264.5M

Revenue Y/Y

-61.17%

Revenue Q/Q

-86.9%

ARCT Earnings

Earnings (TTM)

80.3M

Earnings Y/Y

-143.7%

Earnings Q/Q

-203.54%

Price Action

52 Week Range

37.75

(Low)(High)

Last 7 days

-8.4%

Last 30 days

-17.4%

Last 90 days

12.5%

Trailing 12 Months

86.7%

ARCT Financial Health

Current Ratio

4.71

ARCT Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for ARCT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-09-01	Chivukula Pad	sold	-157,264	31.4527	-5,000	chief scientific officer & coo
2023-08-15	SASSINE ANDY	acquired	21,248	17.374	1,223	chief financial officer
2023-08-01	Chivukula Pad	sold	-174,550	34.91	-5,000	chief scientific officer & coo
2023-07-14	Kummerfeld Keith C	sold	-243,880	35.00	-6,968	see remarks
2023-07-14	Kummerfeld Keith C	acquired	62,408	8.95642	6,968	see remarks
2023-07-14	Chivukula Pad	sold	-875,250	35.01	-25,000	chief scientific officer & coo
2023-07-03	Chivukula Pad	sold	-143,750	28.75	-5,000	chief scientific officer & coo
2023-06-01	Chivukula Pad	sold	-135,800	27.16	-5,000	chief scientific officer & coo
2023-05-11	Chivukula Pad	sold	-239,652	30.24	-7,925	chief scientific officer & coo
2023-05-10	Chivukula Pad	sold	-512,250	30.00	-17,075	chief scientific officer & coo

Which funds bought or sold ARCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-08-24	Alberta Investment Management Corp	new	-	275,385	275,385	-%
2023-08-22	VIRGINIA RETIREMENT SYSTEMS ET AL	new	-	321,216	321,216	-%
2023-08-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-2.56	117,446	825,496	-%
2023-08-21	OSAIC HOLDINGS, INC.	reduced	-7.53	4,606	47,888	-%
2023-08-16	Nuveen Asset Management, LLC	added	27.11	1,850,360	5,401,360	-%
2023-08-15	LAZARD ASSET MANAGEMENT LLC	added	28.29	119,000	341,000	-%
2023-08-15	WELLS FARGO & COMPANY/MN	reduced	-4.38	554,612	4,405,100	-%
2023-08-15	ALLIANCEBERNSTEIN L.P.	added	255	1,778,570	2,325,090	-%
2023-08-15	Formidable Asset Management, LLC	unchanged	-	45,000	429,000	0.09%
2023-08-15	GOLDMAN SACHS GROUP INC	added	19.76	3,273,000	10,833,200	-%

Latest Funds Activity

Are funds buying ARCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARCT

No. of Funds

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	5.46%	1,450,425	SC 13G
Feb 08, 2023	state street corp	8.50%	2,257,846	SC 13G/A
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.45%	1,449,060	SC 13G/A
Feb 01, 2023	federated hermes, inc.	16.00%	4,239,554	SC 13G/A
Jan 31, 2023	blackrock inc.	7.1%	1,884,885	SC 13G/A
Apr 11, 2022	state street corp	12.20%	3,217,957	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	5.15%	1,357,472	SC 13G
Feb 14, 2022	federated hermes, inc.	14.02%	3,694,929	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	0.0%	15,039	SC 13G/A
Feb 11, 2022	state street corp	7.80%	2,056,074	SC 13G

Recent SEC filings of Arcturus Therapeutics Holdings

View All Filings

Date Filed	Form Type	Document
Sep 05, 2023	4	Insider Trading
Sep 01, 2023	144	Notice of Insider Sale Intent
Aug 17, 2023	4	Insider Trading
Aug 14, 2023	8-K	Current Report
Aug 07, 2023	10-Q	Quarterly Report
Aug 07, 2023	424B5	Prospectus Filed
Aug 07, 2023	8-K	Current Report
Aug 03, 2023	4	Insider Trading
Aug 03, 2023	4	Insider Trading
Aug 03, 2023	4	Insider Trading

ARCT Fair Value

Loading...

Peers (Alternatives to Arcturus Therapeutics Holdings)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABBV	271.1B	56.0B	3.50%	10.46%	31.22	4.84	-2.31%	-31.27%
BGNE	258.4B	1.8B	-3.35%	26.15%	-149.17	142.72	69.45%	14.65%
VRTX	91.3B	9.5B	1.11%	26.35%	27.14	9.61	13.83%	5.33%
REGN	88.1B	12.7B	-2.05%	20.27%	20.49	6.95	-10.94%	-24.40%
ALNY	21.7B	1.2B	-8.20%	-15.77%	-20.42	17.55	39.94%	-8.44%
SRPT	11.2B	1.0B	5.15%	8.54%	-12.29	11.11	20.15%	-79.16%
UTHR	10.5B	2.1B	-3.19%	8.81%	12.04	4.97	18.01%	38.16%
MID-CAP
BPMC	3.0B	225.6M	0.06%	-27.49%	-5.4	13.27	-2.11%	21.02%
MDGL	2.9B	-	-11.82%	158.82%	-8.93	-	-	-28.88%
RARE	2.6B	402.9M	1.47%	-16.95%	-3.63	6.49	20.50%	-42.46%
MRTX	2.1B	27.2M	-3.08%	-49.09%	-2.89	78.22	-	-14.43%
SMALL-CAP
CYTK	3.1B	-	-6.35%	-39.40%	-7.31	33.28	34.30%	-149.91%
CPRX	1.3B	302.9M	-15.88%	-2.65%	11.18	4.26	77.72%	112.02%
MGNX	289.9M	152.5M	-10.34%	48.10%	38.91	1.9	127.84%	103.41%
CRBP	28.7M	-	0.62%	3389.00%	-0.62	-	-	-31.51%

Arcturus Therapeutics Holdings News

Returns for ARCT

Cumulative Returns on ARCT

-13.1%

10-Year Cumulative Returns

-2.8%

7-Year Cumulative Returns

22.4%

5-Year Cumulative Returns

-12.9%

3-Year Cumulative Returns

Risks for ARCT

What is the probability of a big loss on ARCT?

100%

Probability that Arcturus Therapeutics Holdings stock will be more than 20% underwater in next one year

100%

Probability that Arcturus Therapeutics Holdings stock will be more than 30% underwater in next one year.

83.1%

Probability that Arcturus Therapeutics Holdings stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-5.9%	264,466,000	281,040,000	205,999,000	51,500,000	40,568,000	15,476,000	12,359,000	8,803,000	8,699,000	9,020,000	9,539,000	10,269,000	11,254,000	19,085,000	20,789,000	25,398,000	25,503,000	17,736,000	15,753,000	11,618,000	9,544,000
Operating Expenses	8.2%	220,440,000	203,729,000	193,822,000	198,420,000	204,502,000	211,041,000	215,211,000	205,092,000	172,105,000	128,748,000	81,063,000	61,528,000	49,191,000	47,552,000	46,302,000	40,805,000	37,650,000	39,383,000	37,564,000	40,474,000	49,832,000
S&GA Expenses	4.5%	51,335,000	49,103,000	46,071,000	45,017,000	43,389,000	42,438,000	41,451,000	39,679,000	34,391,000	28,769,000	23,217,000	15,974,000	14,283,000	13,319,000	12,662,000	14,312,000	14,241,000	19,018,000	20,582,000	24,086,000	32,932,000
R&D Expenses	9.4%	169,105,000	154,626,000	147,751,000	153,403,000	161,113,000	168,603,000	173,760,000	165,413,000	137,714,000	99,979,000	57,846,000	45,554,000	34,908,000	34,233,000	33,640,000	26,493,000	23,409,000	20,365,000	16,982,000	16,388,000	16,900,000
EBITDA	-100.0%	-	208,125,000	12,984,000	-	-	-	-	-19,845,000	-19,952,000	-20,104,000	-20,152,000	-20,694,000	-20,519,000	-20,298,000	-20,410,000	-20,368,666	-20,366,000	-20,478,000	-21,057,000	-	-
EBITDA Margin	-100.0%	-	0.74	0.06	-	-	-	-	-2.25	-2.29	-2.23	-2.11	-2.02	-1.82	-1.06	-0.98	-0.80	-0.80	-1.15	-1.34	-	-
Interest Expenses	-6.8%	2,560,000	2,746,000	813,000	755,000	698,000	684,000	684,000	1,092,000	912,000	692,000	751,000	356,000	531,000	752,000	691,000	677,333	680,000	668,000	146,000	-	-
Earnings Before Taxes	-103.8%	-2,232,000	58,588,000	10,644,000	-	-145,464,000	-204,676,000	-203,674,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-100.0%	-	0.72	0.05	-	-	-	-	-2.47	-2.50	-2.42	-2.28	-2.12	-1.94	-1.14	-1.05	-0.86	-0.85	-1.23	-1.38	-	-
Net Income	-27.8%	80,285,000	111,272,000	9,349,000	-146,661,000	-165,479,000	-198,497,000	-203,674,000	-196,115,000	-163,035,000	-118,717,000	-72,148,000	-52,033,000	-38,462,000	-28,884,000	-25,991,000	-16,013,000	-12,833,000	-22,098,000	-21,785,000	-28,406,000	-39,800,000
Net Income Margin	-100.0%	-	0.40	0.05	-2.85	-4.08	-12.83	-16.48	-22.28	-18.74	-13.16	-7.56	-5.07	-3.42	-1.51	-1.25	-	-	-	-	-	-
Free Cashflow	-100.0%	-	38,855,000	24,267,000	-175,800,000	-149,627,000	-146,531,000	-138,449,000	-102,163,000	-100,055,000	-75,671,000	-44,603,000	-45,127,000	-31,811,000	-13,774,000	-7,263,000	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-8.5%	431	471	450	294	337	342	393	435	449	481	476	323	150	72.00	82.00	87.00	71.00	44.00
Current Assets	-9.3%	385	425	403	247	292	327	379	421	438	470	468	314	142	64.00	74.00	79.00	63.00	42.00
Cash Equivalents	-1.4%	323	328	392	238	283	320	373	414	434	467	463	307	136	59.00	71.00	74.00	56.00	37.00
Net PPE	0.7%	13.00	13.00	12.00	11.00	9.00	8.00	6.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
Liabilities	2.7%	145	142	180	148	166	157	165	175	143	129	80.00	61.00	57.00	55.00	56.00	51.00	49.00	31.00
Current Liabilities	0.2%	90.00	90.00	127	76.00	93.00	107	100	118	71.00	53.00	50.00	28.00	23.00	22.00	21.00	22.00	16.00	13.00
LT Debt, Current	-	-	-	61.00	28.00	27.00	24.00	22.00	-	-	-	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	32.00	36.00	39.00	41.00	42.00	56.00	58.00	14.00	15.00	15.00	15.00	15.00	10.00	10.00	10.00
Shareholder's Equity	-13.4%	285	329	270	146	171	185	228	259	306	353	397	262	93.00	17.00	26.00	36.00	22.00	14.00
Retained Earnings	-18.3%	-339	-287	-338	-455	-420	-398	-347	-308	-254	-200	-143	-112	-91.71	-81.44	-71.67	-60.68	-53.25	-44.87
Additional Paid-In Capital	1.4%	625	617	608	601	591	583	576	568	560	553	540	374	185	98.00	97.00	97.00	75.00	58.00
Shares Outstanding	0.1%	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	23.00	19.00	15.00	12.00	13.00	10.00	10.00

Cashflow (Last 12 Months)
(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Last 12 Months)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	194.0%	132,789	45,161	31,993	-170,763	-145,010	-141,132	-135,043	-99,178	-98,402	-73,953	-42,861	-43,767	-30,726	-12,892	-6,445	-4,670	-8,629	-23,958	-20,760	-27,180	-16,404
Share Based Compensation	3.5%	32,531	31,422	30,611	31,599	29,033	29,299	28,915	24,223	19,341	12,902	6,764	4,735	3,130	2,432	1,982	1,691	1,895	1,989	1,259	2,348	332
Cashflow From Investing	-11.6%	-7,038	-6,306	-7,726	-5,037	-4,617	-5,399	-3,406	-2,985	-1,653	-1,718	-1,742	-1,360	-1,085	-882	-818	1,766	9,748	13,352	22,134	31,292	24,084
Cashflow From Financing	-0.5%	-30,722	-30,559	-2,859	-397	1,515	1,340	48,016	210,987	397,518	483,039	436,145	277,978	112,082	35,305	41,907	62,398	19,706	-	10,204	-76.00	702

ARCT Income Statement

2023-06-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Total revenue	$ 10,519	$ 27,093	$ 90,804	$ 32,337
Operating expenses:
Research and development, net	52,668	38,189	104,436	83,082
General and administrative	13,225	10,993	26,987	21,723
Total operating expenses	65,893	49,182	131,423	104,805
Loss from operations	(55,374)	(22,089)	(40,619)	(72,468)
Loss from equity-method investment		(131)		(515)
Gain (loss) from foreign currency	149	1,217	(179)	1,375
Gain on debt extinguishment			33,953
Finance income (expense), net	3,252	(560)	5,729	(1,124)
Net loss before income taxes	(51,973)	(21,563)	(1,116)	(72,732)
Provision for income taxes	577		680
Net loss	$ (52,550)	$ (21,563)	$ (1,796)	$ (72,732)
Net loss per share:
Basic	$ (1.98)	$ (0.82)	$ (0.07)	$ (2.75)
Diluted	$ (1.98)	$ (0.82)	$ (0.07)	$ (2.75)
Weighted-average shares outstanding:
Basic	26,563	26,425	26,557	26,401
Diluted	26,563	26,425	26,557	26,401
Comprehensive loss:
Net loss	$ (52,550)	$ (21,563)	$ (1,796)	$ (72,732)
Comprehensive loss	(52,550)	(21,563)	(1,796)	(72,732)
Collaboration Revenue [Member]
Revenue:
Total revenue	9,565	$ 27,093	89,294	$ 32,337
Grant Revenue [Member]
Revenue:
Total revenue	$ 954		$ 1,510

ARCT Balance Sheet

2023-06-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 323,471	$ 391,883
Restricted cash	55,000
Accounts receivable	2,799	2,764
Prepaid expenses and other current assets	3,974	8,686
Total current assets	385,244	403,333
Property and equipment, net	12,722	12,415
Operating lease right-of-use asset, net	30,553	32,545
Non-current restricted cash	2,127	2,094
Total assets	430,646	450,387
Current liabilities:
Accounts payable	13,619	7,449
Accrued liabilities	28,763	30,232
Current portion of long-term debt		60,655
Deferred revenue	47,963	28,648
Total current liabilities	90,345	126,984
Deferred revenue, net of current portion	25,725	20,071
Operating lease liability, net of current portion	28,111	30,216
Other non-current liabilities	1,290	2,804
Total liabilities	145,471	180,075
Stockholders’ equity
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,574 at June 30, 2023 and 26,555 at December 31, 2022	27	27
Additional paid-in capital	625,085	608,426
Accumulated deficit	(339,937)	(338,141)
Total stockholders’ equity	285,175	270,312
Total liabilities and stockholders’ equity	$ 430,646	$ 450,387

Arcturus Therapeutics Holdings Inc. Stock Research

Market Summary

ARCT Alerts

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

ARCT Price/Sales (Trailing)

ARCT Profitability

ARCT Fundamentals

ARCT Revenue

ARCT Earnings

Price Action

52 Week Range

ARCT Financial Health

ARCT Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for ARCT

Which funds bought or sold ARCT recently?

Latest Funds Activity

ARCT Alerts

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Recent SEC filings of Arcturus Therapeutics Holdings

ARCT Fair Value

Peers (Alternatives to Arcturus Therapeutics Holdings)

Arcturus Therapeutics Holdings News

Returns for ARCT

Cumulative Returns on ARCT

Risks for ARCT

What is the probability of a big loss on ARCT?

How does ARCT drawdown profile look like?

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Thousands)

ARCT Income Statement

ARCT Balance Sheet

About Arcturus Therapeutics Holdings

Market Summary

ARCT Alerts

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

ARCT Price/Sales (Trailing)

ARCT Profitability

ARCT Fundamentals

ARCT Revenue

ARCT Earnings

Price Action

52 Week Range

ARCT Financial Health

ARCT Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for ARCT

Which funds bought or sold ARCT recently?

Latest Funds Activity

ARCT Alerts

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Recent SEC filings of Arcturus Therapeutics Holdings

ARCT Fair Value

Peers (Alternatives to Arcturus Therapeutics Holdings)

Arcturus Therapeutics Holdings News

Returns for ARCT

Cumulative Returns on ARCT

Risks for ARCT

What is the probability of a big loss on ARCT?

How does ARCT drawdown profile look like?

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Thousands)

ARCT Income Statement

ARCT Balance Sheet

About Arcturus Therapeutics Holdings

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Thousands)